

# AMGEN INC.

ISIN: US0311621009

WKN: 031162100

Asset Class: Stock

## Company

2021/04/12 22:00:00

Price

**248.94**

USD

Difference



-0.00%(-0.01)



## Contact Details

AMGEN, INC.

Tel: 1-805-447-1000

--

Fax: 1-805-447-1010

One Amgen Center Drive

Web: <http://www.amgen.com>

91320-1799 Thousand Oaks

E-mail: -

## Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	21,144,000,000		18,440,000,000		37,618,000,000	
Common stock capital		31,802,000,000		31,531,000,000		31,246,000,000
Fixed assets	41,804,000,000		41,267,000,000		28,798,000,000	
Equity capital of a company		9,409,000,000		9,673,000,000		12,500,000,000
Cash and cash equivalents	6,266,000,000		6,037,000,000		6,945,000,000	
Accrued liabilities		6,968,000,000		8,037,000,000		8,770,000,000
Other assets	-		-		-	
Current liabilities		11,653,000,000		12,835,000,000		13,488,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		41,886,000,000		37,199,000,000		40,428,000,000
Different income		-		-		-
Other liabilities		1,717,000,000		1,218,000,000		1,284,000,000
Total assets	62,948,000,000	62,948,000,000	59,707,000,000	59,707,000,000	66,416,000,000	66,416,000,000

## Balance notes

	2020	2019	2018
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	24,300	23,400	21,500
Equity ratio	14.95%	16.20%	18.82%
Debt-equity ratio	569.02%	517.25%	431.33%

## Others

	2020	2019	2018
Tax Expense Rate	10.68%	14.18%	12.06%

# AMGEN INC.

ISIN: US0311621009

WKN: 031162100

Asset Class: Stock

## Income statement

	2020	2019	2018
Turnover	25,246,000,000	23,261,000,000	23,768,000,000
Net income	7,264,000,000	7,842,000,000	8,394,000,000
EBIT	8,011,957,800	8,258,712,000	8,133,656,300
Operating income before taxes	8,133,000,000	9,138,000,000	9,545,000,000
Cash Flow	10,497,000,000	9,150,000,000	11,296,000,000
Net interest income	-1,413,000,000	-702,000,000	-146,000,000
Research and development expenses	4,207,000,000	4,116,000,000	3,737,000,000
Income taxes	869,000,000	1,296,000,000	1,151,000,000
Result from investments in subsidiaries, associates and other	-	0	0
Revenues per employee	871,974	834,314	927,836

## Board of Directors

## Members of Management Board

Brian Druker	Member of Board of Directors
Robert Williams	Member of Board of Directors
Ronald Sugar	Member of Board of Directors
Tyler Jacks	Member of Board of Directors
Wanda Austin	Member of Board of Directors
Amy Miles	Member of Board of Directors
Charles Holley	Member of Board of Directors
Ellen Kullman	Member of Board of Directors
Fred Hassan	Member of Board of Directors
Greg Garland	Member of Board of Directors
Robert Eckert	Member of Board of Directors
Robert Bradway	Chairman of Managing Board
Darryl Sleep	Member of Executive Committee
David Reese	Member of Executive Committee
Elliott Levy	Member of Executive Committee
Steven Galson	Member of Executive Committee
Arvind Sood	Member of Executive Committee
David Piacquad	Member of Executive Committee
Esteban Santos	Member of Executive Committee
Jonathan Graham	Member of Executive Committee
Linda Louie	Member of Executive Committee
Lori Johnston	Member of Executive Committee
Mike Zahigian	Member of Executive Committee
Murdo Gordon	Member of Executive Committee
Nancy Grygiel	Member of Executive Committee